Capital Raising and Equity Dilution Through ステラファーマ’s New Listing
First written in FY2021. 2 of 5 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「If the second issuance of shares is completed, the company's ownership interest in STELLA PHARMA CORPORATION will be 31.78%, compared with 33.65% at the end of the current consolidated fiscal year, and an equity-change gain of approximately ¥270 million is expected to be recorded in the company's consolidated income statement.」
Regarding STELLA PHARMA CORPORATION, the first issuance under the share and stock acquisition rights issuance program has been completed. The company disclosed the expected decline in its ownership interest and the expected equity-change gain if the program is carried through the second issuance. - FY2022-Q3RestatedAnnual report
「The company's consolidated subsidiary STELLA PHARMA CORPORATION was newly listed on the Mothers market of the Tokyo Stock Exchange on 22 April 2021. As the subsidiary conducted a public offering and other transactions in connection with the listing, capital surplus increased by ¥1,600 million during the cumulative third quarter period of the current consolidated fiscal year. As a result, capital surplus totaled ¥8,912 million at the end of the third quarter accounting period of the current consolidated fiscal year.」
The company confirmed again in the third quarter that capital surplus had increased by ¥1,600 million in connection with STELLA PHARMA CORPORATION's initial public offering and public offering of shares and other transactions. - FY2022-Q2RestatedAnnual report
「The company's consolidated subsidiary STELLA PHARMA CORPORATION was newly listed on the Mothers market of the Tokyo Stock Exchange on 22 April 2021. As the subsidiary conducted a public offering and other transactions in connection with the listing, capital surplus increased by ¥1,600 million during the cumulative second quarter period of the current consolidated fiscal year. As a result, capital surplus totaled ¥8,912 million at the end of the second quarter accounting period of the current consolidated fiscal year.」
The company confirmed again in the second quarter that capital surplus had increased by ¥1,600 million in connection with STELLA PHARMA CORPORATION's initial public offering and public offering of shares and other transactions. - FY2022-Q1AdvancedAnnual report
「The company's consolidated subsidiary STELLA PHARMA CORPORATION was newly listed on the Mothers market of the Tokyo Stock Exchange on 22 April 2021. As the subsidiary conducted a public offering and other transactions in connection with the listing, capital surplus increased by ¥1,600 million during the cumulative first quarter period of the current consolidated fiscal year.」
The company disclosed that the public offering and third-party allotment conducted in connection with STELLA PHARMA CORPORATION's initial public offering had been completed, increasing capital surplus on a consolidated basis by ¥1,600 million. - FY2021AchievedAnnual report
「On 22 April 2021, the company was listed on the Mothers market of the Tokyo Stock Exchange. In connection with the listing, STELLA PHARMA CORPORATION raised funds through the issuance of new shares. As a result, the company's voting rights ownership ratio became 46%.」
STELLA PHARMA CORPORATION completed its initial public offering in April 2021 and raised funds through a public offering. Following a third-party allotment in May 2021, the company's voting rights ownership ratio became 44%.